Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275093 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
NCT00275093: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00275093 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275093, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus in treating patients with metastatic solid tumor or lymphoma that cannot be removed by surgery who have different levels of liver function. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Temsirolimus may have different effects in patients who have changes in their liver function
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275093
The ClinicalTrials.gov registry entry for NCT00275093 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00275093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275093 about?
NCT00275093 is a clinical study titled "Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function". This phase I trial is studying the side effects and best dose of temsirolimus in treating patients with metastatic solid tumor or lymphoma that cannot be removed by surgery who have different levels of liver function. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes n...
What is the current status of trial NCT00275093?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2005-12.
What interventions are being tested in trial NCT00275093?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00275093?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.